011040.Kq
The company operates in the Pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
Business. The company operates in the Pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the Pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 31,809 million, which is 34% of total assets. However, the free cash flow is negative at KRW -17,043 million, indicating that capital expenditures are outpacing operating cash flow. The debt-to-equity ratio is 0.2, suggesting a conservative capital structure with limited leverage.
Profitability metrics show a return on equity (ROE) of 3.73% and a return on assets (ROA) of 2.65%, both below the typical thresholds for high-performing pharmaceutical firms. The gross profit margin is 59.3%, which is in line with industry norms, but the operating margin is only 3.6%, indicating inefficiencies in cost management or pricing power.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts. The absence of segment or geographic breakdown in the financial data limits the ability to assess risk distribution.
The company's growth trajectory is constrained, with no disclosed revenue growth rates or forward-looking guidance. The capital expenditure of KRW -20,512 million suggests a focus on maintaining rather than expanding operations. The outlook for the current fiscal year does not include significant revenue or margin expansion.
Risk factors include a negative net cash position after subtracting total debt, which could limit flexibility in capital allocation. The dilution risk is assessed as low, with no recent share issuance or dilutive events reported. However, the negative free cash flow may pressure the company to seek external financing in the future.
Recent events include the publication of the latest financial results, which show a net income of KRW 8,529 million. No significant regulatory or litigation events were disclosed in the most recent filings. The company's investor relations page provides limited forward-looking guidance, focusing on maintaining operational stability.
- The company has a conservative capital structure with a debt-to-equity ratio of 0.2.
- Free cash flow is negative, indicating that capital expenditures exceed operating cash flow.
- ROE and ROA are below typical thresholds for high-performing pharmaceutical firms.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company's growth trajectory is constrained, with no significant revenue or margin expansion expected.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 011040.KQ Market data — financials · 2026-05-26
- Kyung Dong Pharmaceutical Co Ltd Market data — analyst estimates · 2026-05-26
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
4 tracked-field change(s) detected vs prior analysis; max severity: medium.
- Dilution risk— → lowlow
- Liquidity risk— → mediumlow
- Activity— → Pharmaceuticals & Medical Researchmedium
- Economic sector— → Healthcaremedium